RT305

RT305 is a preclinical-stage topical drug candidate being developed by Revio Therapeutics for the treatment of dermatological disorders. It is part of the company's reformulation pipeline, which focuses on enhancing the delivery and efficacy of established pharmaceutical agents through optimized delivery systems. RT305 specifically utilizes a specialized device applicator for topical administration to improve the therapeutic profile of a proven drug. While the identity of the active ingredient and its specific molecular target remain proprietary, the program is designed to leverage Revio's delivery technology to optimize outcomes in dermatology.